# Biospecimen logistics for clinical trials Temperature-controlled, chain-of-custody transport and storage of patient-derived samples between trial sites, central labs, and biorepositories. Source: https://en.bioecon.ru/technology/biospecimen-logistics-for-clinical-trials/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: NACE 52.29 (Other courier activities) | OECD: Bio-pharma | Regulator: FDA (USA), EMA (EU), NMPA (CN)] Biospecimen logistics for clinical trials is the temperature-controlled, chain-of-custody transport and storage of patient-derived samples — blood, tissue, and cells — between trial sites, central laboratories, and biorepositories. It is governed by GxP, Good Distribution Practice (GDP), and IATA temperature-control regulations, and it is scaling rapidly as cell-and-gene-therapy (CGT) trials and decentralized studies multiply. The segment is consolidating around GDP- and IATA CEIV Pharma-certified courier networks: Marken alone operates across 43 countries with some 1,406 staff and roughly GBP 168.9 million in annual revenue, PCI Pharma Services has committed over $1 billion to expand US and European capacity, and cryogenic storage now reaches −190°C for viable cell assets. The key directions of biospecimen logistics are: 1. **Cold-Chain Courier Networks:** GDP- and IATA CEIV Pharma-certified couriers move time-critical, temperature-sensitive biospecimens across borders with validated packaging and real-time monitoring. 2. **Cryogenic Storage & Biorepository:** Automated cryogenic storage (down to −190°C) preserves viable cells, tissues, and CGT starting material across the research spectrum from discovery to therapeutic products. 3. **Decentralized & Direct-to-Patient Trials:** Home health visits and mobile phlebotomy shift sample collection closer to the patient, requiring last-mile cold-chain and integrated logistics platforms. 4. **Chain-of-Custody Digital Tracking:** IoT temperature loggers, barcode/RFID chain-of-custody, and electronic data capture link each sample to its analytical record without loss of identity. ### Sectoral value chain ``` [Collection] ──> [Packaging] ──> [Transport] ──> [Storage / Biorepository] │ (Chain of Custody) │ ▼ [Trial Data] <─── [Central Lab / Analytics] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Collection** | Drawing and stabilizing patient biospecimens at trial sites or in-home visits. | **In:** Patients, kits.
**Out:** Raw biospecimens. | | **Packaging** | Validated temperature-controlled shippers (controlled ambient, chilled, frozen, cryogenic). | **In:** Raw biospecimens.
**Out:** Packaged samples. | | **Transport** | GDP/CEIV-certified courier movement across sites, labs, and borders. | **In:** Packaged samples.
**Out:** In-transit samples. | | **Storage / biorepository** | Cryogenic and monitored warehousing of viable and archive samples. | **In:** In-transit samples.
**Out:** Catalogued inventory. | | **Central lab / analytics** | Testing, omics, and biomarker analysis of received specimens. | **In:** Catalogued inventory.
**Out:** Analytical results. | | **Trial data** | Linking results back to the electronic trial record via chain-of-custody. | **In:** Analytical results.
**Out:** Trial data. | Cross-cutting technologies of the sector: - **Cold-Chain Courier Networks:** GDP- and IATA CEIV Pharma-certified transport with validated thermal packaging and real-time temperature monitoring. - **Cryogenic Biorepository:** Automated −150°C to −190°C storage for viable cells and CGT starting material. - **Chain-of-Custody Tracking:** IoT loggers and barcode/RFID systems that preserve sample identity from draw to data. --- ## US The United States leads the market through specialty pharma couriers and biorepository specialists anchored to the world's largest concentration of clinical trials and CGT developers. ### Specialty couriers, CGT logistics, cryogenic storage - **World Courier:** A specialty pharma logistics leader advancing cell-and-gene-therapy trial logistics, often in partnership with CROs such as IQVIA. - **Marken:** A UPS Healthcare company operating across 43 countries with around 1,406 staff and roughly GBP 168.9 million in revenue, headquartered in Durham, North Carolina. - **Azenta Life Sciences:** Provides sample and biological-material storage and automated cryogenic systems (e.g. CryoArc) spanning discovery to clinical trials. --- ## CN China's biospecimen logistics is anchored by large third-party medical-testing networks that combine a national specimen-collection footprint with central-laboratory capacity. ### Third-party testing networks, national specimen footprint, central labs - **KingMed Diagnostics:** Guangzhou Kingmed Diagnostics Group (603882.SS), one of China's largest third-party medical-testing and specimen-network operators. - **National footprint:** Dense collection and referral networks move biospecimens from hospitals to central labs at provincial scale. - **Clinical-trial uptake:** Domestic CRO and pharma growth drives demand for compliant clinical biospecimen handling. --- ## EU Europe combines air-freight cold-chain infrastructure with CDMO-linked clinical distribution, expanding capacity to serve cross-border multi-region trials. ### Airfreight cold chain, CDMO capacity, cross-border trials - **DHL Medical Express:** Operates a growing temperature-controlled airfreight cold-chain network with dedicated capacity and aviation routes for time-critical pharma and biologics. - **PCI Pharma Services:** Has committed over $1 billion to expand US and European sterile fill-finish and drug-device capabilities, integrating clinical supply with distribution. - **Regulatory baseline:** EU GDP and EMA requirements set a stable compliance framework for cross-border specimen and investigational-product movement. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **World Courier** | 🇺🇸 USA | *CGT & specialty pharma courier* | GDP / IATA CEIV Pharma | commercial | | **Marken** | 🇺🇸 USA | *Clinical-trial logistics* | UPS Healthcare, 43-country network | commercial | | **Azenta Life Sciences** | 🇺🇸 USA | *Cryogenic biorepository* | Automated −190°C storage | commercial | | **DHL Medical Express** | 🇩🇪 Germany | *Airfreight cold-chain network* | Temperature-controlled aviation capacity | commercial | | **PCI Pharma Services** | 🇬🇧 UK | *Clinical supply & distribution* | $1B+ US/Europe expansion | commercial | | **KingMed Diagnostics** | 🇨🇳 China | *Third-party specimen network* | National central-lab footprint (603882.SS) | commercial | --- ## Tech stack and innovations The segment's stack couples validated thermal packaging, IoT monitoring, and biorepository automation, all wrapped in GxP/GDP data integrity. 1. **Cold-Chain Courier Networks:** - GDP- and IATA CEIV Pharma-certified couriers move samples in validated shippers across controlled ambient, chilled, frozen, and cryogenic ranges. - Real-time temperature and location monitoring protects sample integrity across 43-country networks such as Marken's. 2. **Cryogenic Biorepository:** - Automated cryogenic storage (down to −190°C, e.g. Azenta CryoArc) preserves viable cells and CGT starting material with sample-management software. - Enables long-term archive and retrieval for retrospective biomarker and longitudinal analyses. 3. **Chain-of-Custody Tracking:** - IoT loggers, barcode/RFID, and electronic data capture bind each biospecimen to its analytical and consent record end to end. - Underpins FDA 21 CFR Part 11 data-integrity expectations and audit-ready trial records. --- ## Value chains and production pipelines ### Industrial pipeline of clinical biospecimen logistics (GDP / IATA CEIV Pharma / 21 CFR Part 11) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Collection │ ───> │ 2. Packaging │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Storage / Biorepository│ <─── │ 3. Transport │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Central Lab / Analytics│ ───> │ 6. Trial Data Linkage │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Collection Patient biospecimens are drawn and stabilized at trial sites or through in-home visits, labelled with unique identifiers that carry consent and chain-of-custody from the first touchpoint. #### Stage 2: Packaging Specimens are placed in validated temperature-controlled shippers — controlled ambient, chilled, frozen, or cryogenic (dry-shipper) — selected to the sample's stability profile and transit time. #### Stage 3: Transport GDP- and IATA CEIV Pharma-certified couriers move packaged samples across sites, borders, and central labs with real-time temperature and location monitoring and documented handoffs. #### Stage 4: Storage / biorepository Samples are received into monitored, often automated biorepository space, including cryogenic storage down to −190°C for viable cells and CGT assets, with inventory catalogued for retrieval. #### Stage 5: Central lab / analytics Specimens are queued for testing, omics, and biomarker analysis at central or specialty laboratories, with results bound to each sample's chain-of-custody identifier. #### Stage 6: Trial data linkage Analytical results are linked back to the electronic trial record under 21 CFR Part 11 data-integrity expectations, closing the loop between patient sample and study outcome and enabling retrospective and longitudinal analyses.